Cargando...

Anti-CD20 monoclonal antibodies: historical and future perspectives

Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto-immune B-lymphocytes by rituximab has demonstrated substantial benefits for patients with a variety of B-cell lymphomas, as...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Lim, Sean H., Beers, Stephen A., French, Ruth R., Johnson, Peter W.M., Glennie, Martin J., Cragg, Mark S.
Formato: Artigo
Idioma:Inglês
Publicado: Ferrata Storti Foundation 2010
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2805725/
https://ncbi.nlm.nih.gov/pubmed/19773256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2008.001628
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!